SKYE Punit Dhillon buys $100.0B worth of shares
Jan 04, 2026, 11:43 AM
-14.24%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Punit Dhillon bought 1,000,000 shares of SKYE on 7 August at $100000.00 per share, worth a total of $100.0B. They now own 1,000,000 SKYE shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.